Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients

BACKGROUND: A new approach to the treatment of COPD includes controlling inflammation because of its important role in exacerbation of the disease. Recently, roflumilast has been added as a therapeutic option for COPD. Roflumilast is an oral phosphodiesterase-4 inhibitor that targets inflammatory ce...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Chron Obstruct Pulmon Dis
Main Authors: Porpodis, Konstantinos, Domvri, Kalliopi, Zarogoulidis, Paul, Petridis, Dimitrios, Tsirgogianni, Katerina, Papaioannou, Antonis, Hatzizisi, Olga, Kioumis, Ioannis, Liaka, Alexandra, Kikidaki, Violeta, Lampaki, Sofia, Organtzis, John, Zarogoulidis, Konstantinos
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2015
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4474389/
https://ncbi.nlm.nih.gov/pubmed/26109853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S83205
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados